Clinical Trial Update: SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study [Phase 2]

View source ↗

Summary

A Phase II, open-label study evaluating SHR-A1811 plus pertuzumab as neoadjuvant therapy for early or locally advanced HR-positive, HER2-positive breast cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• SHR-A1811

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: SHR-A1811, HER2-Postive Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING